Develop novel products to treat cancer. Focus on clinical-stage programs. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
For a bank, strength is measured by capital buffers and reserves — not cash minus debt.
Clearly below the class average.
Sales are growing strongly for its sector.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 42% below its peak. The market has trimmed its expectations for the company.
This is a fund, not a company — there are no company accounts here to point to a strength. What it holds is what it is.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 0/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 31/100. For a turnaround signal, the stock first needs to close the gap with the market.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 41/100.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.